# NAD+: The Cell's Most-Recycled Molecule > NAD+: Research Overview — Friend With Peptides — A literature summary of NAD+ and its precursors NMN and NR within Longevity & Cellular Health research: the redox and signalling roles, the CD38 decline hypothesis, the randomized human trials, and the safety and regulatory picture. **01 / LONGEVITY & CELLULAR HEALTH** The coenzyme every cell uses to move electrons, the enzymes that compete to consume it, and what actually happened in the human trials when it was topped up. ## The short version NAD+ — nicotinamide adenine dinucleotide — is the molecule cells use to shuttle electrons around. Almost every step that turns food into usable energy either hands an electron to NAD+ or takes one back from its reduced partner, NADH, which means a cell is not really spending NAD+ so much as passing it back and forth all day [4]. It has a second job, and that one does spend it. A set of enzymes chew NAD+ up as raw material in order to work: *sirtuins*, which adjust how DNA is packaged and how mitochondria behave; *PARPs*, which patch DNA damage; and *CD38*, an enzyme on the cell surface that rises with age and inflammation [4][6]. When those enzymes are busy, the shared pool shrinks. Tissue NAD+ falls as people get older, and topping it back up is the idea behind everything sold in this corner of the supplement aisle. The topping-up part demonstrably works: precursors reliably raise blood NAD+ in human trials [2][5]. Whether that translates into ageing or feeling differently is where the evidence thins out sharply [1]. ## What it is NAD+ stands for nicotinamide adenine dinucleotide. Chemically it is two nucleotides joined at their phosphate groups — a nicotinamide ring at one end, an adenine ring at the other. It exists in two states that interconvert: NAD+, the oxidized form that accepts electrons, and NADH, the reduced form that carries them. That pairing is the entire point of the molecule, and the ratio between the two forms is one of the readouts a cell uses to judge how well fed it is. Cells do not absorb finished NAD+ from food. They build it, largely by recycling nicotinamide through a salvage pathway whose rate-limiting enzyme is NAMPT. This is why the market sells precursors rather than the coenzyme itself: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) sit further along that salvage route, while intact oral NAD+ is poorly taken into cells whole. Regulatory footing varies by form and it is worth keeping straight. NAD+ precursors are marketed as dietary supplements, with NMN's supplement status challenged by the FDA on the grounds that it was investigated as a drug — an argument that has left the marketplace genuinely uncertain. Injectable and intravenous NAD+ is typically compounded rather than FDA-approved, and a compounded NAD+ injection has been subject to a Class I recall for elevated bacterial endotoxin. None of these forms is an approved treatment for ageing anywhere. ## How it works Two jobs, and they compete for the same molecule. The first is redox chemistry. Glycolysis, the TCA cycle and oxidative phosphorylation all pass electrons to NAD+ and retrieve them from NADH; the mitochondrial NAD+/NADH couple feeds complex I of the respiratory chain. Nothing is consumed in this loop — the molecule cycles indefinitely. The second job does consume it. Three families of enzymes cleave NAD+ in order to function: the sirtuins (SIRT1 through SIRT7), NAD+-dependent deacylases that regulate gene expression and mitochondrial performance; the PARPs, chiefly PARP1, which mount the DNA-damage response; and CD38 with its relative CD157, ectoenzymes sitting on the cell surface [4]. All three draw on one pool, so a cell under DNA stress or chronic inflammation is spending NAD+ that the sirtuins would otherwise have had. CD38 is the reason the age-related decline has a proposed *cause* rather than only a description. Its activity rises with age, and mice engineered without CD38 are protected against the age-related fall in tissue NAD+, retaining SIRT3 activity and better mitochondrial and metabolic function into old age [6]. That result is what turned "NAD+ goes down" into "NAD+ goes down for a reason that might be addressable", and it remains the mechanistic spine of the entire precursor field. ## What the research shows The human trials in this area agree about one thing and argue about the rest. **Raising the marker works, reproducibly.** In a multicentre, double-blind, placebo-controlled, dose-dependent trial, oral NMN at 300, 600 and 900 mg per day for 60 days raised blood NAD+ dose-dependently at both day 30 and day 60 across all groups against placebo (p≤0.001), with 600 mg per day identified as the optimal dose and no safety issues reported at any dose [2]. Nicotinamide riboside behaves the same way: 100 to 1000 mg per day for eight weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively in healthy overweight adults, with no flushing, no elevation of LDL cholesterol and no significant adverse-event difference from placebo [5]. **Some functional endpoints moved with it.** That same 60-day NMN trial reported improved walking distance and quality-of-life scores against placebo, and its biological-age measure did not increase over the study [2]. A separate ten-week trial of 250 mg per day of oral NMN in prediabetic, postmenopausal women found a significant increase in muscle insulin sensitivity measured by hyperinsulinaemic-euglycaemic clamp — with no change in body composition and no change in HbA1c [3]. **Mechanistic work in tissue keeps widening.** A 2025 study using human myocardium and an established murine model of heart failure with preserved ejection fraction found that repleting oxidized NAD+ restored the ketogenic enzyme HMGCS2 by deacetylating it, increased fatty-acid oxidation and rescued cardiac function — and failed to rescue it when HMGCS2 was knocked down in cardiomyocytes, which is the control that makes the mechanism credible rather than merely correlated [7]. **And the synthesis is cautious.** A 2025 narrative review in Nature Metabolism concluded that human trials of NAD+ precursors in ageing have shown limited efficacy, that age-related NAD+ decline has been consistently observed in only a limited number of human studies, and that the body of data on tissue-specific NAD+ dynamics remains sparse — arguing for more clinical work rather than continued extrapolation from rodents [1]. ## Reported effects, cautions & safety The signed corpus behind this desk carries no curated set of community-reported effects for NAD+, and this page will not invent one. A molecule sold simultaneously in capsules, IV bags and compounded injections attracts far more testimonial than any of it can be reliably attributed to. What the published record supports on safety is narrow, and reassuring as far as it reaches. Oral nicotinamide riboside across 100-1000 mg per day for eight weeks produced no significant adverse-event difference from placebo, no flushing, no LDL elevation and no disruption of one-carbon metabolism [5]. The 60-day NMN trial reported no safety issues at any of its three doses [2]. Both studies were short, and neither was designed to detect anything rare. The open concerns are worth stating plainly: - **Oral NAD+ itself is poorly taken into cells intact.** Many researchers consider precursors the only rational oral route and plain "NAD+" capsules largely ineffective. - **Marker movement is not outcome movement.** Blood NAD+ rises dependably; longevity and disease prevention in humans remain unproven, and much of the strongest anti-ageing data comes from rodents and may not extrapolate [1]. - **Intravenous NAD+ wellness therapy is marketed well ahead of its evidence.** Infused NAD+ is cleared rapidly from plasma, and infusions run too quickly can cause chest or abdominal discomfort, flushing and nausea. - **Compounded injectable NAD+ carries a contamination risk** that is not theoretical: the FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin. - **A theoretical oncology concern exists.** NAD+ supports proliferating cells and its role in cancer is dual and context-dependent, so caution is generally advised in cancer populations. - **Product quality varies widely.** Supplement-grade material differs in purity and actual content, and third-party testing is not guaranteed. Nothing on this page is a recommendation, and no figure here is offered as a dose for a person to take. ## Where it fits in everyday upkeep Of the three molecules on this desk, NAD+ is the one closest to genuinely ordinary. It is not exotic, and the trials that exist enrolled exactly the sort of people the maintenance framing is aimed at: middle-aged adults [2], prediabetic postmenopausal women [3], healthy overweight adults [5]. The endpoints are ordinary too — how far someone can walk, how well muscle answers insulin. That ordinariness cuts both ways. It makes NAD+ the best-evidenced member of this group by a wide margin, and it also makes the effects small enough to be genuinely hard to feel. A change in muscle insulin sensitivity measured by clamp is a real physiological finding [3]; it is not a sensation, and nobody should expect it to announce itself. The honest position, and the one the 2025 review takes, is that the first half of the hypothesis is established and the second half is not [1]. Tissue NAD+ falls with age, CD38 is a plausible reason why [6], and precursors raise the circulating pool [2][5]. Whether topping up a pool restores the functions that pool serves is the question the next decade of trials has to answer. [MOTS-c](/mots-c) and [Epitalon](/epitalon) sit further from that answer, not closer. --- A friendly literature digest on the peptides filed under everyday cellular upkeep — enthusiasm allowed, citations required, advice never given.